Revelation Biosciences, Inc. (REVB) Financials
REVB Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 12.5 million | 2.4 million |
| March 31, 2026 | 15.0 million | 2.1 million |
| Dec. 31, 2025 | 11.6 million | 2.7 million |
| Sept. 30, 2025 | 12.9 million | 1.9 million |
REVB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -2.6 million | 401417 |
| March 31, 2026 | -3.3 million | 470997 |
| Dec. 31, 2025 | -2.0 million | 370166 |
| Sept. 30, 2025 | -1.6 million | 874 |
REVB Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| June 30, 2026 | -3.3 million |
| March 31, 2026 | -3.0 million |
| Dec. 31, 2025 | -2.5 million |
| Sept. 30, 2025 | -1.9 million |
REVB Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 11.5 million | 550546 | 739916 |
| March 31, 2026 | 14.1 million | - | 638183 |
| Dec. 31, 2025 | 10.7 million | - | 723771 |
| Sept. 30, 2025 | 12.7 million | - | - |
REVB Shares Outstanding
REVB Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 39628 | 1.9 million | 1.7 million | - |
| March 31, 2026 | 71879 | 1.4 million | 1.7 million | -7203 |
| Dec. 31, 2025 | - | 964190 | 1.6 million | - |
| Sept. 30, 2025 | - | 922857 | 1.0 million | - |
REVB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 7203 |
| Dec. 31, 2025 | - | 5852 |
| Sept. 30, 2025 | - | 6765 |
REVB
Price: $1.11
52 week price:
Earnings Per Share: 26.55 USD
P/E Ratio: 0.04
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 562000
Market Capitalization: 4.3 million